Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 201,563,808
  • Shares Outstanding, K 2,291,800
  • Annual Sales, $ 48,677 M
  • Annual Income, $ 11,732 M
  • 60-Month Beta 0.64
  • Price/Sales 4.35
  • Price/Cash Flow 11.54
  • Price/Book 3.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.38
  • Number of Estimates 3
  • High Estimate 1.41
  • Low Estimate 1.32
  • Prior Year 1.20
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.86 +0.29%
on 02/26/20
99.84 -12.75%
on 02/12/20
-6.76 (-7.20%)
since 01/24/20
3-Month
86.86 +0.29%
on 02/26/20
99.84 -12.75%
on 02/12/20
-5.01 (-5.44%)
since 11/26/19
52-Week
74.97 +16.19%
on 04/22/19
99.84 -12.75%
on 02/12/20
+6.63 (+8.24%)
since 02/26/19

Most Recent Stories

More News
Monofocal IOLs Market Fundamental Analysis By Top Key Players Alcon, Inc. (US) (Novartis AG (Switzerland))

An analysis of Global has been provided within the latest report launched by Big Market Research that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over...

CZMWF : 132.2000 (-0.97%)
HOCPF : 90.6500 (+1.00%)
NVS : 87.11 (-0.96%)
STAA : 28.75 (-5.52%)
VRX.TO : 30.80 (-3.33%)
Premium Intraocular Lens Market 2025 - Innovative Ideas by Top Key Players Alcon, Inc. (US) (Novartis AG (Switzerland))

Global 2020-2025 research report is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges with key company profiles and strategies of players....

CZMWF : 132.2000 (-0.97%)
HOCPF : 90.6500 (+1.00%)
NVS : 87.11 (-0.96%)
STAA : 28.75 (-5.52%)
VRX.TO : 30.80 (-3.33%)
Epilepsy Therapeutics Market Clinical Research and Detailed Analysis Report, Forecast to 2025 Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Johnson & Johnson

The report offers a comprehensive analysis of the market. This report focused on market past and present growth globally. Global research on Global Epilepsy Therapeutics Industry presents a market overview,...

ABT : 81.36 (+0.28%)
GSK : 41.90 (+1.01%)
NVS : 87.11 (-0.96%)
VRX.TO : 30.80 (-3.33%)
GlaxoSmithKline Plc top Key Players in Epilepsy Drugs Market Collaborate with Clover Biopharmaceuticals on Coronavirus Vaccine

GSK : 41.90 (+1.01%)
NVS : 87.11 (-0.96%)
VRX.TO : 30.80 (-3.33%)
PFE : 34.72 (+2.33%)
Global Adult Vaccines Market Witness Highest Growth in near future| Johnson and Johnson, Emergent BioSolutions Inc and Merck & Co. Inc

Global Adult Vaccines Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property Analysis, Market...

ABT : 81.36 (+0.28%)
AZN : 47.57 (+1.04%)
CSLLY : 101.8400 (-3.38%)
GSK : 41.90 (+1.01%)
JNJ : 143.68 (-0.67%)
MRK : 79.94 (-0.41%)
NVS : 87.11 (-0.96%)
PFE : 34.72 (+2.33%)
VRX.TO : 30.80 (-3.33%)
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

- Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as annualized...

NVS : 87.11 (-0.96%)
Genetron Health and InnoCare Team Up In Partnership To Accelerate the Development and Commercialization of Novel Drugs for Cancer Treatment

Genetron Holding Limited ("Genetron Health"), a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma Tech Co., Ltd....

NVS : 87.11 (-0.96%)
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

JNJ : 143.68 (-0.67%)
SNY : 49.45 (+0.90%)
AZN : 47.57 (+1.04%)
RHHBY : 42.1500 (+0.96%)
PFE : 34.72 (+2.33%)
MRK : 79.94 (-0.41%)
NVS : 87.11 (-0.96%)
Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat

Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.

RHHBY : 42.1500 (+0.96%)
NVS : 87.11 (-0.96%)
VRTX : 232.04 (+0.89%)
PBYI : 10.61 (-6.19%)
Intellia (NTLA) to Report Q4 Earnings: What's in Store?

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

NVS : 87.11 (-0.96%)
SAGE : 63.65 (-1.24%)
CLVS : 7.48 (-6.38%)
NTLA : 12.30 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 90.29
1st Resistance Point 88.70
Last Price 87.11
1st Support Level 86.19
2nd Support Level 85.27

See More

52-Week High 99.84
Fibonacci 61.8% 90.34
Fibonacci 50% 87.41
Last Price 87.11
Fibonacci 38.2% 84.47
52-Week Low 74.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar